MIH
INDP icon

Meitav Investment House’s Indaptus Therapeutics INDP Stock Holding History

Meitav Investment House’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,080
Closed -$420K – 425
2021
Q2 		$420K Hold
1,080
– – 0.01% 324
2021
Q1 		$529 Sell
1,080
-1,079
-50% -$566K 0.01% 263
2020
Q4 		$835K Buy
2,159
+1,079
+100% +$471K 0.03% 195
2020
Q3 		$609K Hold
1,080
– – 0.03% 231
2020
Q2 		$686K Hold
1,080
– – 0.04% 188
2020
Q1 		$477K Sell
1,080
-2
-0.2% -$1.51K 0.04% 235
2019
Q4 		$1.21M Hold
1,082
– – 0.09% 143
2019
Q3 		$1.69M Sell
1,082
-16
-1% -$47.6K 0.12% 99
2019
Q2 		$10.7M Sell
1,098
-132
-11% -$1.66M 0.71% 41
2019
Q1 		$20.2M Sell
1,230
-14
-1% -$245K 1.13% 24
2018
Q4 		$21M Sell
1,244
-36
-3% -$491K 1.3% 21
2018
Q3 		$15.1M Buy
1,280
+186
+17% +$1.77M 0.73% 42
2018
Q2 		$11.4M Buy
1,094
+377
+53% +$4.18M 0.51% 56
2018
Q1 		$10.2M Sell
717
-29
-4% -$411K 0.52% 57
2017
Q4 		$8.61M Buy
+746
New +$11.6M 0.5% 59

Other funds holding INDP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $1.92B AUM 23.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Meitav Investment House's INDP Position: Q3 2021 in Review

Meitav Investment House sold out of Indaptus Therapeutics (INDP) in Q3 2021, closing a stake of 1,080 shares — an estimated $420K sold.

Meitav Investment House first reported a position in INDP in Q4 2017 and held it in 15 quarters. The position peaked at $21M in Q4 2018. 14 funds tracked by Wall St. Rank hold INDP as of Q3 2021.

  • Meitav Investment House reported no remaining Indaptus Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Meitav Investment House sold 1,080 Indaptus Therapeutics shares in Q3 2021, an estimated $420K.
  • Meitav Investment House first reported a position in Indaptus Therapeutics in Q4 2017 and held it in 15 quarters.
  • Meitav Investment House's Indaptus Therapeutics position peaked at $21M in Q4 2018.
  • 14 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2021.

Based on Meitav Investment House's 13F filing for Q3 2021, filed 3 Nov 2021.